Follow The Filings

INFU Infusystem Holdings Inc.

Health Care, filed as INFUSYSTEM HLDGS INC (COM), Equity As of 2026 Q2 among managers we track Quote on Google Finance, opens in a new tab

Sold by 1 manager in 2026 Q2

  • 1 Owner
  • Max 0.0%
  • $6M
  • 1 reduce

In 2026 Q2 First Eagle Investment Management trimmed Infusystem.

Who owns this now

Largest portfolio weights among holders, up to 0.0% (First Eagle Investment Management). Not free-float ownership.

  1. First Eagle Investment Manage... Reduce 0.01%

Who owns INFU

Sorted by value, long equity only, as of 2026 Q2.

History
First Eagle Investment Management 0.01% Reduce −14.1% 620,000 $6M History

1 current, options excluded

Weight bar: held both quarters added sold at this quarter’s reported price

Insider trades

Open-market buys and sales by INFU's executives, directors and 10% owners in the last 12 months, from their Form 4s

All INFU insider trades
  • $150K bought by 3 insiders
  • None no sales outside a trading plan
  • None no planned (10b5-1) sales
  1. Paul Andrew Gendron Director
    Buy
    $44K 5,000 shares at $8.88 +7.7% to stake
    Traded May 8 Filed May 12
    ↗
  2. Carrie Lachance CEO
    Buy
    $26K 3,000 shares at $8.71 +1.3% to stake
    Traded May 8–11 Filed May 12
    ↗
  3. Barry G Steele CFO
    Buy
    $61K 7,000 shares at $8.71 +7.8% to stake
    Traded May 8 Filed May 12
    ↗
  4. Barry G Steele CFO
    Buy
    $19K 2,064 shares at $9.16 +2.4% to stake
    Traded Mar 2 Filed Mar 2
    ↗

Also filed in the last 12 months, not counted as buying or selling: 12 share withholdings for taxes, 8 option exercises, 4 stock grants, and 1 other transaction.

SEC filings

Recent issuer filings from EDGAR, 20 shown.

Filed Form Detail Links
8-K 7.01 Filing Doc
8-K 2.02 Filing Doc
8-K 7.01 Filing Doc
10-Q Filing Doc
SCHEDULE 13G — Filing Doc
8-K 7.01 Filing Doc
8-K 7.01 Filing Doc
8-K 5.02 Filing Doc
8-K 5.02,5.07 Filing Doc
10-Q Filing Doc
8-K 2.02 Filing Doc
8-K 7.01 Filing Doc
DEF 14A Filing Doc
8-K 4.01 Filing Doc
8-K 7.01 Filing Doc
10-K Filing Doc
8-K 7.01 Filing Doc
8-K 2.02 Filing Doc
SCHEDULE 13G/A — Filing Doc
8-K 7.01 Filing Doc

Source: SEC EDGAR submissions, updated 6 days ago. All on EDGAR

Financials

US-GAAP annual figures by fiscal year, as tagged in Form 10-K. Each value links to its SEC filing.

Income statement

Metric FY2023 FY2024 FY2025
Gross profit $63.11M $70.4M $80.3M
Net income $0.872M $2.34M $6.63M

Balance sheet

Metric FY2023 FY2024 FY2025
Total current assets $30.62M $32.16M $36.34M
Total non-current assets * $72.3M $71.45M $64.22M
Total assets $102.92M $103.61M $100.56M
Total current liabilities $15.71M $17.66M $20.18M
Total non-current liabilities * $34.9M $28.42M $23.05M
Total equity $52.3M $57.53M $57.33M

Cash flow

Metric FY2023 FY2024 FY2025
Cash from operations $11.22M $20.46M $24.41M
Cash from investing -$6.73M -$13.24M -$6.79M
Cash from financing -$4.42M -$6.92M -$14.96M
Net change in cash $0.066M $0.296M $2.66M

Source: SEC companyfacts (US-GAAP 10-K). A * marks a computed figure, not a single XBRL tag. Fiscal years are as the issuer labels them. Follow The Filings does not adjust or audit these figures.

Ownership over time

13Fs that reported it each quarter. Click a bar for that quarter’s holders.